Thursday, June 25, 2026
🇺🇸 FDA

Clinical Tools · VTE · Deep Vein Thrombosis

Wells DVT Score Calculator

Calculate pre-test probability of deep vein thrombosis using the standard Wells DVT criteria. Built for VTE diagnostic pathways, D-dimer and ultrasound triage, and anticoagulant trial endpoint literacy.

Quick Answer

The Wells DVT score estimates pre-test probability of deep vein thrombosis from active cancer, paralysis, bed rest, tenderness, leg swelling, calf asymmetry, pitting edema, collateral veins, and alternative diagnosis. Scores ≤0 suggest DVT unlikely (D-dimer pathway); ≥1 warrants compression ultrasound. Pair with Wells PE for full VTE diagnostic literacy relevant to anticoagulant and thrombolytic trial endpoints.

Wells DVT score
Total = cancer + immobilization + bedridden/surgery + tenderness + leg swelling + calf >3 cm + pitting edema + collateral veins + prior DVT − alternative diagnosis
Nine criteria add +1 each; alternative diagnosis subtracts 2. ≤0 low · 1–2 moderate · ≥3 high probability DVT.

Calculate Wells DVT Score

Select all criteria that apply to the patient. Most criteria add 1 point; the alternative-diagnosis criterion subtracts 2 points.

Wells DVT criteria

Apply the alternative-diagnosis deduction only when another cause is genuinely at least as likely as DVT on clinical assessment.

DVT probability

-

-

-

Total score
-
−2 to 9
Criteria selected
-
of 10

How to Use the Wells DVT Calculator

1
Evaluate the patient with suspected DVT: history of cancer, immobilization, surgery, prior VTE, and focused leg examination.
2
Select each Wells criterion that applies. Subtract 2 points only if an alternative diagnosis is at least as likely as DVT.
3
Calculate the total score and review the low (≤0), moderate (1–2), or high (≥3) probability band.
4
Follow institutional VTE pathways for D-dimer testing and compression ultrasonography. Confirmed DVT triggers anticoagulation decisions per guideline and trial evidence—not Wells score alone.

Worked Example

Example calculation

Patient: 58-year-old with 4 days of left calf pain and swelling after long-haul travel. No cancer. No immobilization or recent surgery. Localized deep-venous tenderness present. Calf circumference 38 cm left vs 34 cm right (10 cm below tibial tuberosity). Pitting edema on the left. No collateral veins. No prior DVT. Cellulitis considered less likely than DVT.

Criteria met: Localized tenderness (+1), calf swelling >3 cm (+1), pitting edema (+1).

Total Wells DVT: 3 points — high probability DVT. Proceed to compression ultrasonography per pathway; D-dimer alone is insufficient for rule-in in this band.

Wells DVT Interpretation Bands

Low probability ≤ 0 points

Estimated DVT prevalence ~5% in validation cohorts. Negative high-sensitivity D-dimer may exclude DVT without initial ultrasound in appropriate outpatients.

Moderate probability 1 – 2 points

Intermediate pre-test probability. D-dimer and/or imaging strategy depends on local protocol; many pathways proceed to compression ultrasonography.

High probability ≥ 3 points

Estimated DVT prevalence ~50% or higher in high-score cohorts. Definitive imaging (compression ultrasonography) recommended; do not defer based on D-dimer alone.

VTE Anticoagulant Trials for Pharma Professionals

After objective DVT confirmation, treatment trials compare anticoagulant regimens on recurrent VTE and bleeding. Landmark programs include EINSTEIN-DVT (rivaroxaban vs enoxaparin/VKA), AMPLIFY (apixaban vs enoxaparin/warfarin), and Hokusai-VTE (edoxaban vs warfarin). Primary efficacy endpoints are typically recurrent VTE; major bleeding and CRNMB are key safety endpoints adjudicated per ISTH or protocol definitions.

Wells DVT stratifies suspected (not yet confirmed) disease. Diagnostic accuracy and D-dimer algorithm studies define how referral populations are triaged before therapeutic trial enrollment. Sponsors documenting baseline VTE workup in registries may capture Wells scores at presentation; treatment trials require imaging-confirmed endpoints. Extended-duration trials (EINSTEIN CHOICE, AMPLIFY-EXT) address recurrence prevention after initial therapy—distinct from diagnostic scoring.

Bleeding risk on anticoagulation after confirmed VTE may be contextualized with HAS-BLED in patients with comorbid atrial fibrillation or polypharmacy. Use our HAS-BLED Score Calculator for complementary bleeding-risk assessment alongside VTE treatment decisions.

D-Dimer and Imaging Pathway Context

The Wells DVT score integrates with age-adjusted or fixed D-dimer thresholds in outpatient algorithms. Low-probability patients (Wells ≤0 in two-tier models, or ≤1 in some three-tier adaptations) with negative high-sensitivity D-dimer can often avoid immediate ultrasound. High-probability patients (Wells ≥3) should proceed to compression ultrasonography because elevated pre-test probability reduces the negative predictive value of D-dimer.

Inpatient, pregnant, and post-operative populations may require modified pathways not fully captured by outpatient Wells validation. Whole-leg versus proximal-leg ultrasound protocols vary by institution. Wells scoring does not apply to patients already on therapeutic anticoagulation for unrelated indications without re-evaluating symptoms.

For pulmonary embolism probability assessment in patients with chest symptoms, see our Wells PE Score Calculator. DVT and PE pathways overlap when concomitant PE is suspected.

Limitations and Caveats

Wells DVT was validated in selected symptomatic outpatient cohorts. Performance may differ in hospitalized patients, those with recurrent symptoms on anticoagulation, or subgroups with high baseline VTE prevalence. The alternative-diagnosis item depends on clinician judgment and can be misapplied to inappropriately lower pre-test probability.

The score estimates probability—it does not diagnose DVT. False negatives and false positives occur. Clinical gestalt, serial testing, and repeat imaging may be required when suspicion persists despite initial negative workup.

Anticoagulation initiation requires confirmed VTE and assessment of bleeding risk, renal function, drug interactions, and patient preferences. For stroke-risk context in patients with concurrent atrial fibrillation, see our CHA₂DS₂-VASc Score Calculator.

Interpretation Reference Table

Wells DVT score Probability category Estimated DVT prevalence Typical next step
≤ 0 Low ~5% High-sensitivity D-dimer; ultrasound if D-dimer elevated
1 – 2 Moderate ~17–28% D-dimer and/or compression ultrasonography per local protocol
≥ 3 High ~50–75% Compression ultrasonography; do not rely on D-dimer alone to rule in

Evidence & Sources

Frequently Asked Questions

The Wells score for deep vein thrombosis (DVT) estimates the pre-test probability of DVT in symptomatic outpatients. It assigns points for clinical features associated with DVT (cancer, immobilization, leg swelling, tenderness, prior DVT, collateral veins) and subtracts 2 points when an alternative diagnosis is at least as likely as DVT. The result stratifies patients into low, moderate, or high probability categories to guide D-dimer testing and imaging decisions.
Each of nine criteria adds 1 point if present: active cancer (treatment within 6 months or palliative), paralysis/paresis/plaster immobilization, bedridden >3 days or major surgery within 12 weeks, localized deep-venous tenderness, entire leg swollen, calf swelling >3 cm versus the other leg (measured 10 cm below tibial tuberosity), pitting edema confined to the symptomatic leg, collateral superficial veins (non-varicose), and previously documented DVT. If an alternative diagnosis is at least as likely as DVT, subtract 2 points. There is no fixed maximum; scores can range from −2 to 9.
Standard two-tier interpretation: score ≤0 indicates low probability of DVT (~5% prevalence in validation cohorts); score ≥1 indicates DVT likely (~28% prevalence). Three-tier interpretation used here: ≤0 low probability, 1–2 moderate probability, ≥3 high probability. Low-probability patients may proceed to D-dimer testing with imaging only if D-dimer is elevated; high-probability patients typically warrant definitive imaging (compression ultrasonography) without relying on D-dimer alone.
Both scores share the name Wells but use different criteria and cutoffs. The Wells DVT score assesses leg symptoms and deep-vein thrombosis probability; the Wells PE score (often called Wells criteria for PE) evaluates pulmonary embolism probability with criteria such as clinical signs of DVT, heart rate, immobilization, prior PE/DVT, hemoptysis, and malignancy. They answer different diagnostic questions and should not be interchanged.
In low-probability patients (Wells ≤0 or ≤1 depending on local protocol), a negative high-sensitivity D-dimer often excludes DVT without ultrasound. In moderate- or high-probability patients, D-dimer has limited rule-out utility because elevated rates of true positives reduce negative predictive value; compression ultrasonography is the preferred next step. Always follow institutional VTE pathways and current ACCP or ESC guidelines.
Emergency departments, primary care VTE clinics, and thrombosis services use Wells DVT at presentation to standardize pre-test probability documentation, reduce unnecessary imaging, and align D-dimer utilization with guideline algorithms. Integrated care programs and anticoagulation clinics may reference Wells scores at referral to contextualize diagnostic workup before initiating therapeutic anticoagulation.
Phase 3 VTE treatment trials (EINSTEIN-DVT, AMPLIFY, Hokusai-VTE) enroll patients with objectively confirmed DVT or PE and compare anticoagulant regimens on recurrent VTE and bleeding endpoints. Wells DVT may appear in observational diagnostic studies, registry enrollment criteria, or baseline characteristics of referral populations—not as a primary trial endpoint. Diagnostic accuracy studies (Wells validation, D-dimer algorithms) inform how suspected DVT cohorts are triaged before therapeutic trial enrollment.
VTE treatment trials typically report recurrent VTE (fatal and non-fatal), major bleeding, clinically relevant non-major bleeding, and all-cause mortality as primary or key secondary endpoints. Extended treatment trials (e.g., EINSTEIN CHOICE, AMPLIFY-EXT) add recurrent VTE prevention after initial therapy. HAS-BLED and other bleeding scores may stratify safety analyses in anticoagulated VTE populations alongside stroke-prevention programs.
Active cancer adds 1 point to the Wells DVT score and independently increases VTE risk through hypercoagulability, stasis, and treatment effects. Cancer-associated thrombosis may warrant extended anticoagulation per guideline and trial data (e.g., LITE, CLOT). A high Wells score in a cancer patient supports prompt imaging but does not alone confirm DVT—objective diagnosis remains mandatory before therapeutic anticoagulation.
If a clinician judges that an alternative diagnosis (e.g., cellulitis, ruptured Baker cyst, muscle strain, superficial thrombophlebitis) is at least as likely as DVT, 2 points are subtracted. This reflects clinical gestalt and reduces false-positive pre-test probability. It requires careful assessment; inappropriate use can delay DVT diagnosis. Document the suspected alternative when applying this criterion.
Wells DVT was validated in selected outpatient cohorts and may perform differently in inpatients, pregnant patients, or those with prior DVT on anticoagulation. The alternative-diagnosis item introduces subjectivity. The score estimates probability—it does not diagnose DVT. Compression ultrasonography, whole-leg ultrasound, or other imaging per protocol remains required for definitive diagnosis before long-term anticoagulation.
No. Wells DVT is a pre-test probability tool to guide D-dimer and imaging algorithms, not a substitute for physical examination, clinical judgment, or definitive diagnostic studies. Anticoagulation initiation must follow confirmed VTE diagnosis, approved labels, institutional protocols, and specialist assessment—particularly in pregnancy, renal impairment, active bleeding, or cancer-associated thrombosis.

Related Tools

WPE Wells PE Score HB HAS-BLED Score C2V CHA₂DS₂-VASc Score

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.